These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

298 related articles for article (PubMed ID: 24168050)

  • 1. Molecular pathways and potential therapeutic targets in glioblastoma multiforme.
    Wardak Z; Choe KS
    Expert Rev Anticancer Ther; 2013 Nov; 13(11):1307-18. PubMed ID: 24168050
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular characterizations of glioblastoma, targeted therapy, and clinical results to date.
    Bastien JI; McNeill KA; Fine HA
    Cancer; 2015 Feb; 121(4):502-16. PubMed ID: 25250735
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SnapShot: glioblastoma multiforme.
    Kotliarova S; Fine HA
    Cancer Cell; 2012 May; 21(5):710-710.e1. PubMed ID: 22624719
    [No Abstract]   [Full Text] [Related]  

  • 4. Cellular signaling molecules as therapeutic targets in glioblastoma multiforme.
    Jagannathan J; Prevedello DM; Dumont AS; Laws ER
    Neurosurg Focus; 2006 Apr; 20(4):E8. PubMed ID: 16709039
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The challenges associated with molecular targeted therapies for glioblastoma.
    Jue TR; McDonald KL
    J Neurooncol; 2016 May; 127(3):427-34. PubMed ID: 26900075
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic advances in the treatment of glioblastoma: rationale and potential role of targeted agents.
    Reardon DA; Wen PY
    Oncologist; 2006 Feb; 11(2):152-64. PubMed ID: 16476836
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evolving strategies: future treatment of glioblastoma.
    Chamberlain M
    Expert Rev Neurother; 2011 Apr; 11(4):519-32. PubMed ID: 21469925
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular targeted therapy in recurrent glioblastoma: current challenges and future directions.
    Patel M; Vogelbaum MA; Barnett GH; Jalali R; Ahluwalia MS
    Expert Opin Investig Drugs; 2012 Sep; 21(9):1247-66. PubMed ID: 22731981
    [TBL] [Abstract][Full Text] [Related]  

  • 9. STAT3 as a Therapeutic Target for Glioblastoma.
    Liu Y; Li C; Lin J
    Anticancer Agents Med Chem; 2010 Sep; 10(7):512-9. PubMed ID: 20879983
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Deregulated signaling pathways in glioblastoma multiforme: molecular mechanisms and therapeutic targets.
    Mao H; Lebrun DG; Yang J; Zhu VF; Li M
    Cancer Invest; 2012 Jan; 30(1):48-56. PubMed ID: 22236189
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular targets in glioblastoma.
    Zorzan M; Giordan E; Redaelli M; Caretta A; Mucignat-Caretta C
    Future Oncol; 2015; 11(9):1407-20. PubMed ID: 25952786
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current Development of Glioblastoma Therapeutic Agents.
    Wang Z; Peet NP; Zhang P; Jiang Y; Rong L
    Mol Cancer Ther; 2021 Sep; 20(9):1521-1532. PubMed ID: 34172531
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Designer therapies for glioblastoma multiforme.
    Sathornsumetee S; Rich JN
    Ann N Y Acad Sci; 2008 Oct; 1142():108-32. PubMed ID: 18990124
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antiangiogenic therapies in glioblastoma multiforme.
    McNamara MG; Mason WP
    Expert Rev Anticancer Ther; 2012 May; 12(5):643-54. PubMed ID: 22594899
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Natural products as promising targets in glioblastoma multiforme: a focus on NF-κB signaling pathway.
    Soukhtanloo M; Mohtashami E; Maghrouni A; Mollazadeh H; Mousavi SH; Roshan MK; Tabatabaeizadeh SA; Hosseini A; Vahedi MM; Jalili-Nik M; Afshari AR
    Pharmacol Rep; 2020 Apr; 72(2):285-295. PubMed ID: 32152926
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Advances in Experimental Targeted Therapy and Immunotherapy for Patients with Glioblastoma Multiforme.
    Polivka J; Polivka J; Holubec L; Kubikova T; Priban V; Hes O; Pivovarcikova K; Treskova I
    Anticancer Res; 2017 Jan; 37(1):21-33. PubMed ID: 28011470
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Necroptosis: a novel therapeutic target for glioblastoma.
    Jiang YG; Peng Y; Koussougbo KS
    Med Hypotheses; 2011 Mar; 76(3):350-2. PubMed ID: 21075544
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting the DNA Damage Response to Overcome Cancer Drug Resistance in Glioblastoma.
    Ferri A; Stagni V; Barilà D
    Int J Mol Sci; 2020 Jul; 21(14):. PubMed ID: 32664581
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic targeting of EGFR-activated metabolic pathways in glioblastoma.
    Gao Q; Lei T; Ye F
    Expert Opin Investig Drugs; 2013 Aug; 22(8):1023-40. PubMed ID: 23731170
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Monoamines in glioblastoma: complex biology with therapeutic potential.
    Caragher SP; Hall RR; Ahsan R; Ahmed AU
    Neuro Oncol; 2018 Jul; 20(8):1014-1025. PubMed ID: 29126252
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.